• Most comprehensive and unbiased assessment of prognostic biomarkers in MM resulting in a robust and parsimonious model.
Introduction
Multiple myeloma (MM) is a hematological malignancy of terminally differentiated plasma cells (PCs) that reside within the bone marrow 1 . It arises as a result of complex chromosomal translocations or aneuploidy with approximately 25,000-30,000 patients diagnosed annually in the United States 2,3 . The disease's clinical course depends on a complex interplay of molecular characteristics of the PCs and patient socio-demographic factors. While progress has been made with novel treatments extending the time to disease progression (and overall survival) for the majority of patients, a subset of 15%-20% of newly diagnosed MM patients are characterized by an aggressive disease course with rapid disease progression and poor overall survival regardless of initial treatment [4] [5] [6] . Accurately predicting which newly diagnosed patients are at high-risk is critical to designing studies that will lead to a better understanding of myeloma progression and facilitate the discovery of novel therapies that meet the needs of these patients.
To date most MM risk models use patient demographic data, clinical laboratory results and cytogenetic assays to predict clinical outcome. High risk defining cytogenetic alterations typically include deletion of 17p and gain of 1q as well as t(14;16), t (14;20) , and most commonly t(4;14), which leads to juxtaposition of MMSET with the immunoglobulin heavy chain locus enhancer, resulting in overexpression of the MMSET oncogene 4 . While cytogenetic assays, in particular fluorescence in situ hybridization (FISH), are widely available, their risk prediction is sub-optimal and recently developed classifiers have used gene expression data to more accurately predict risk [7] [8] [9] . To investigate possible improvements to models of newly diagnosed myeloma progression, we organized the crowd sourced Multiple Myeloma DREAM Challenge, focusing on predicting high-risk, defined as disease progression or death prior to 18 months from diagnosis. This benchmarking effort combined eight datasets, four which provided participants with clinical, cytogenetic, demographic and gene expression data to facilitate model development, and four hidden, independent data sets (N = 823 unique patient samples) for unbiased validation. Over 800 people participated in this Challenge, resulting in the submission of 171 predictive algorithms for objective evaluation. Several models submitted to the Challenge demonstrated improved accuracy over existing state-of-the-art, published models.
Analysis of top performing methods identified high expression of PHF19, a histone methyltransferase, as the gene with the strongest association with myeloma progression, with greater predictive power than the expression level of the known high risk gene MMSET. We developed a four parameter model using age, ISS, and PHF19 and MMSET expression that performs as well as more complex models having many more gene features. The parsimony of this model should facilitate its translation to the clinic. Significantly, we showed that knock down of PHF19 shifts myeloma cell lines into a less proliferative state. To our knowledge, this is the first DREAM Challenge to both nominate and experimentally validate a candidate biomarker and, as such, demonstrates the biological and clinical impact of crowdsourced efforts.
Methods

Datasets:
The Challenge includes five microarray and three RNA-seq expression datasets, annotated with clinical characteristics such as gender, age, ISS, and cytogenetics (Table 1) [9] [10] [11] [12] [13] [14] . In all datasets, the expression assay was performed on CD138+ PCs isolated from bone marrow aspirates or blood of newly diagnosed patients. Data were split into training and validation datasets ( Table 1) .
Three institutes provided RNA-sequencing data. The Multiple Myeloma Research Foundation (MMRF) provided an additional training dataset from its publicly available CoMMpass study (release IA9). Collaborating with the Myeloma Genome Project / Dana Farber Cancer Institute (MGP-DFCI) access was provided to data from their clinical trial where patients were randomized into a standard treatment arm and an aggressive treatment arm that included autologous stem cell transplant (ASCT) and high dose therapy 15 
Assessing Model Performance
To identify top performing teams we employed two metrics to assess the accuracy of submitted models within a given validation cohort: the integrated area under the curve (iAUC) and balanced accuracy curve (BAC). While the AUC is a widely accepted metric of prediction accuracy, it is sensitive to the specific time threshold used to differentiate high and low patient risk. The myeloma research community has not yet reached a consensus on the time point that best separates patients into risk groups, though there is a general agreement that it lies between 1 and 2 years for progression free survival (PFS). We therefore chose the more robust iAUC for the primary metric, with a sliding PFS threshold between 12 and 24 months at weekly increments. iAUCs computed in each validation cohort were combined into a weighted average (wiAUC) with each cohort iAUC weighted by the square of the number of high-risk patients.
Using the wiAUC we computed the Bayes factor, K, to identify statistically tied top performing predictors (see supplemental Methods). Predictors with K p < 3 are considered tied with the top scoring model and the weighted BAC (wBAC) was used as a tie-breaking metric in order to determine the final top performing model, with weighting by the square of the number of high risk patients in each dataset (see supplemental text).
In vitro studies For Functional assessment of PHF19
Studies to determine the functional importance of PHF19 were performed using standard assays and are described in the supplemental text. In brief, tetracycline inducible short hairpin RNA (TRIPZ shRNA) was used to knockdown PHF19 expression in two MM cell lines (JJN3 and ARP1). A non-silencing scrambled TRIPZ shRNA was used as a control. PHF19 knockdown (KD) after doxycycline induction was measured by quantitative real time polymerase chain reaction (qRT-PCR) and western blotting. Cell viability (Cell Titer Blue, Promega), cell cycle (Vybrant DyeCycle Stain, Thermo Scientific) and apoptosis (Annexin V, Biolegend) were assessed and differences between the PHF19 KD cells and control group were analyzed.
Results
Top Challenge Models Outperform Baseline and Published Myeloma Predictors
To develop and assess prognostic models of high-risk in MM, we assembled eight data sets totaling 2447 patients annotated with overall survival (OS) and progression-free survival (PFS; Table 1 ). We asked participants to predict whether a patient was high-risk as defined as disease progression or death prior between 12-24 months since diagnosis (see Methods). Participants developed prognostic models using clinical features (e.g., age, sex, International Staging System (ISS), and cytogenetic features) and gene expression utilizing four training datasets. Challenge participants submitted models to be evaluated against four validation cohorts sequestered in the cloud (Figure 1 , Table 1 , see supplement text). Model predictions were benchmarked against each other and comparator models ( Of 42 finalized models submitted to the Challenge, 11 exceeded the performance of the age plus ISS baseline model (Figure 2, wiAUC=0 .6207). The top-performing predictor, developed by researchers at the Genome Institute of Singapore (GIS), outperformed all Challenge participant models (wiAUC = 0.6721) as well as the published comparator models UAMS-70 (wiAUC=0.6414) and EMC-92 (wiAUC=0.6042, Figure 2 ).
Combining Clinical Features and Gene Expression Features Improves Myeloma Risk Prediction Accuracy
After the Challenge submission period ended, Challenge organizers and top performing teams assessed which features had the largest impact on model performance. ISS was the most important model feature in GIS's top-performing model as measured by the mean decrease in Gini coefficient (see methods). A DNA repair signature previously associated with poor prognosis 24 was the second most important feature, while age ranked third (supplemental Figure 1 ).
To assess whether age and/or ISS explained the difference in model performance between the top-performing model and published comparator models, we extended the UAMS-70 7 and EMC-92 23 models to include age and/or ISS and assessed their performance (Figure 2 ; see Supplemental Methods). The addition of these clinical features improved performance of both published models: EMC-92 wiAUC= from 0.6042 versus EMC-92+age+ISS wiAUC=0.658 and UAMS-70 wiAUC=0.6414 versus UAMS-70+ISS wiAUC=0.6667 as has been suggested previously 13, 25 . Adding ISS to the UAMS-70 model improved its accuracy such that it was tied with the top-performing model (i.e., its Bayes factor K < 3; Figure 2a -b).
Top-Performing Challenge Methods Identify PHF19 as a Novel Myeloma High Risk Biomarker
The top-performing model implemented a wisdom of the crowd approach, utilizing clinical features and published myeloma signatures that summarize the expression of gene sets. The second-place SUGO model instead included individual genes as features, utilizing a univariatebased feature selection approach to identify genes to include in their model. In each of the four training datasets the SUGO team computed each gene's effect size, z, via the concordance index between overall survival and the gene's expression. These effect sizes were combined across training sets using Stouffer's method 26 without weighting to yield a single meta-z per gene. The meta concordance index was calculated using two expression normalization procedures, with one nominating PHF19 as the most important gene and the second identifying CDKN3 (See Supplement Methods).
We replicated this analysis in both the training and validation expression datasets using PFS in place of OS to increase statistical power. We also weighted studies according to their number of high risk patients when applying Stouffer's method. This univariate analysis also found previously described myeloma risk genes MMSET and CKS1B with large values in the tail of the meta-z distribution (Figure 3a) , validating this approach. The meta-z values of these genes were surpassed by PHF19, the top-ranked gene regardless of normalization procedure (not shown) in both the training and validation datasets (Figure 3a) .
Given that PHF19's association with progression was replicated in the validation datasets, we next asked whether it could improve the performance of the GIS model which did not include single genes. The GIS model uses penalized logistic regression over features ranked and selected based on mean decrease in Gini coefficient calculated via a random forest (see Supplemental Methods). We added PHF19 expression into this feature selection process and found that it ranked higher than all other features, except ISS and a previously-published DNA repair signature 24 (supplemental Figure 2) .
Incorporating PHF19 and MMSET expression with Age and ISS Identifies a Simple Model of High Risk MM
Given that both PHF19 and MMSET are histone modifiers playing a role in H3K36 methylation we checked whether their expression is correlated (Figure 3b ). Expression of MMSET and PHF19 do not appear to have an association. As has previously been shown, MMSET expression is clearly affected by the t(4;14) translocation with the immunoglobulin enhancer driving high MMSET expression, but expression of PHF19 is not correlated. However, subsetting by t(4;14) reveals a modest linear relationship between MMSET and PHF19 expression in samples lacking the translocation (r = 0.423) while there is no such relationship in the t(4;14) positive samples (r = -0.067).
Given the impact of PHF19 on model performance and MMSET's status as a reported myeloma risk marker, we checked to see if a model composed of age, ISS, PHF19 and MMSET could perform as well as one using the features of the top-performing extended comparator model (UAMS-70 plus age plus ISS). We constructed a Cox proportional-hazards model of the two feature sets and found that the four parameter model (wiAUC=0.693) out-performed the UAMS-70-based model in the validation cohort (wiAUC=0.667; Figure 3c ) placing it on par with the winning algorithm.
Knockdown of PHF19 Leads to Decreased Proliferation through Cell Cycle Arrest in Multiple Myeloma Cell Lines
To determine whether PHF19 is functionally important for the malignant growth of MM cells, we used lentiviral-expressed shRNA directed against PHF19. We transduced JJN3 and ARP1 MM cell lines with a shRNA targeting PHF19 or a scrambled control shRNA and selected out transduced cells. shRNA induced cells showed knockdown (KD) of >90% PHF19 RNA and protein relative to the control after 72 hrs and 168 hrs for the JJN3 and ARP1 cell lines, respectively (Figure 4a and 4b) . KD of PHF19 led to significant inhibition of proliferation in the JJN3 and ARP1 MM cell lines compared to scrambled shRNA control (Figure 4c-d) confirming the recent finding of PHF19's effect on proliferation in MM cell lines 27 . To identify the mechanism of growth inhibition, we performed cell cycle analysis and observed a significant arrest of MM cells in the G0/G1 stage with PHF19 KD compared to the scrambled control shRNA (Supplemental Figure 3a) . This was seen consistently in both cell lines examined (Supplemental Figure 3b ). We further investigated the effect of PHF19 KD on apoptosis and necrosis, but did not find significant differences at the examined time points (Supplemental Figure 3c -e). These results demonstrate that PHF19 is functionally relevant in MM and that reduction of PHF19 leads to a decrease in cell proliferation via cell cycle arrest.
Discussion
In the course of the crowd sourced Multiple Myeloma DREAM Challenge we benchmarked 171 prediction models and found that the accuracy of gene expression-based models benefited from the addition of clinical data, specifically: age and ISS improved AUC-based metrics by approximately 6% while an indicator of whether a patient received an ASCT improved the metric by roughly 5%. As such, expression-based patient stratification efforts should incorporate age and ISS, and possibly include an ASCT indicator for any post hoc analysis.
Additionally, we show for the first time that expression of PHF19 is a stronger predictor of MM progression than the expression level of the high risk marker MMSET, which is particularly overexpressed in patients with the high risk translocation t (4;14) . This strong association was likely missed in earlier studies given that PHF19 expression is not associated with any cytogenetic feature while several therapeutic advances over the last 20 years have made it difficult to model outcome across multiple studies from different periods. Furthermore, PHF19 has not been found to be significantly mutated in sequencing-based studies 28, 29 , suggesting that its overexpression is not directly related to genomic alterations within the PHF19 gene. We also show that a simple four feature predictor composed of age, ISS, and expression of PHF19 and MMSET performs similarly to more complex models with many more gene expression features included (Supplemental Figure 4 ). This simplicity may allow the model to be more easily adopted in a clinical setting where only two genes would need to be measured.
Apart from its prognostic value, we show that PHF19 has functional importance in MM. Knockdown of PHF19 led to a significant reduction of growth and cell cycle arrest ex-vivo, suggesting that PHF19 may play a role in transitioning cells into a highly proliferative state in MM. PHF19 has been shown to be a major modulator of histone methylation thereby regulating transcriptional chromatin activity 30 . PHF19 directly recruits the polycomb repressive complex 2 (PRC2) via binding to H3K36me3 and leads to activation of enhancer of zeste homolog 1 and 2 (EZH1/EZH2) as enzymatic subunits of PRC2, thereby resulting in tri-methylation of H3K27 31, 32 . This process has been shown to enforce gene repression and is known to promote tumor growth in a variety of cancers 33 . While MMSET has also been shown to regulate histone methylation, its role as an epigenetic modulator is less well understood. Some reports have suggested that MMSET leads to transcriptional repression through generation of H4K20me 34 , H3K27me3 35 or H3K36me3 35 , while other studies show that MMSET enhances transcription through generation of H4K20me2 36 and H3K36me2 35 . In contrast to MMSET, PHF19 expression is present in all MM subgroups and is preferentially overexpressed in high risk MM. These results are indicative of a strong correlation between increased histone methylation, in particular H3k27 trimethylation, and disease aggressiveness. Further work will be necessary to elucidate the mechanisms of PHF19 in MM biology and any interplay with MMSET. 
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